BMS awarded 2018 ENERGY STAR Partner of the Year Sustained Excellence Award

3 Apr 2018

The company’s environmental efforts honored for the fourth consecutive year.

The US Environmental Protection Agency (EPA) and the US Department of Energy have recognized Bristol-Myers Squibb (BMS) with an ENERGY STAR Partner of the Year Sustained Excellence Award for outstanding efforts to improve the energy efficiency of facilities worldwide. BMS has earned the ENERGY STAR Partner of the Year award for the past 4 consecutive years.

BMS awarded 2018 ENERGY STAR Partner of the Year Sustained Excellence Award

The award confirms BMS’s long-term commitment to environmental responsibility through driving sustainable improvements in energy with a goal of reducing the company use or resources across its drug discovery, development and delivery pipeline.

“We are proud to receive the ENERGY STAR Partner of the Year designation for 4 years, and to increase our recognition with the Sustained Excellence Award,” said Carol Ryerkerk Powell, vice president of Environment, Health, Safety and Sustainability, BMS. “To continue developing innovative medicines for our patients, we have to embrace our responsibility to support our environment, employees and communities. We look forward to our continued partnership with ENERGY STAR to better advance our energy management programs and demonstrate our leadership within the pharmaceutical industry.”

BMS was recognized for the following accomplishments:
  • Achieving an annual energy intensity improvement of more than $% globally, contributing to an 11.3% reduction in energy consumption since 2013.
  • Assisting the ENERGY STAR program with energy treasure hunt training for healthcare energy managers and conducting a treasure hunt with an external organization, St Joseph’s Medical Center in Bloomington, Illinois.
  • Achieving the ENERGY STAR Challenge for Industry at two sites and taking the challenge at eight new sites.
  • Hosting the first ENERGY STAR showcase event at a pharmaceutical facility that engaged employees, local government officials and ENERGY STAR industrial partners.
  • Earning ENERGY STAR certification at two office buildings.
  • Actively participating in the ENERGY STAR Focus on Energy Efficiency in Pharmaceutical Manufacturing and the ENERGY STAR industrial partnership.
  • Investing over $42.4 million across 342 energy projects to achieve an annualized savings of over $18.3 million since 2010.
  • In addition to the company’s recognition as an ENERGY STAR Partner of the Year, BMS’s R&D site in Hopewell, New Jersey, and the manufacturing site in New Brunswick, New Jersey earned the 2017 Challenge for Industry recognition. The ENERGY STAR Challenge for Industry is a national call-to-action to improve energy efficiency of America’s manufacturers by 10% or more. By taking the ENERGY STAR Challenge, sites set a goal to reduce their energy intensity by 10% within 5 years.

    Read More

    Related tags

    Market News

    Related news

    BIA Separations expands with new upstream processing facility

    BIA Separations expands with new upstream processing facility

    20 Sep 2018

    Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

    Read more 
    Sanofi to refocus two global business units

    Sanofi to refocus two global business units

    19 Sep 2018

    The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

    Read more 
    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

    18 Sep 2018

    China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

    Read more 
    Recipharm connects to European Hub for serialisation compliance

    Recipharm connects to European Hub for serialisation compliance

    18 Sep 2018

    Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

    Read more 
    Bosch to unveil new laboratory device for continuous manufacturing

    Bosch to unveil new laboratory device for continuous manufacturing

    18 Sep 2018

    The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

    Read more 
    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

    17 Sep 2018

    Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

    Read more 
    Cambrex expands manufacturing footprint with acquisition

    Cambrex expands manufacturing footprint with acquisition

    16 Sep 2018

    Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

    Read more 
    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    NMPA approves fruquintinib capsules for metastatic colorectal cancer

    13 Sep 2018

    Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

    Read more 
    Aptar Pharma to showcase an industry first

    Aptar Pharma to showcase an industry first

    12 Sep 2018

    PureHale is a new portable drug delivery device designed for upper respiratory care.

    Read more 
    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

    11 Sep 2018

    The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

    Read more